Abstract: The present disclosure relates to a directional pixel for a high-angular resolution, wide field of view, multiple view display. The design teaches a directional pixel comprising a substrate, one or more pixel driving circuits, one or more nano- or micro-scale subpixels, and one or more directional optical guiding surfaces, wherein each of said one or more subpixels is comprised of a light emitting device emitting a light beam and an optical microcavity housing said light emitting device. The optical microcavity is comprised of a plurality of reflective surfaces to specifically manipulate and tune said light beam, wherein one or more of said reflective surfaces is a light propagating reflective surface which propagates said light beam out of said microcavity, and said light propagating reflective surface is connected to said one or more directional optical guiding surfaces to direct said light beam at a specific angle.

Abstract: A dietary supplement composition is formulated in a therapeutic amount to treat and alleviate symptoms of joint pain. The composition includes pro-inflammatory low molecular weight microbial fermented sodium hyaluronate fragments having a molecular weight of 0.5 to 300 kilodaltons (kDa) in an oral dosage form.

Abstract: A dietary supplement composition is formulated in a therapeutic amount to treat and alleviate symptoms of joint pain. The composition includes pro-inflammatory low molecular weight microbial fermented sodium hyaluronate fragments having a molecular weight of 0.5 to 300 kilodaltons (kDa) in an oral dosage form.

Abstract: A dietary supplement composition and associated method of use has the composition formulated in a therapeutic amount to treat and alleviate symptoms of joint pain in a person having joint pain. The composition includes astaxanthin and microbial fermented, low molecular weight hyaluronic acid or sodium hyaluronate (hyaluronan). The composition also includes at least one of a phospholipid, glycolipid, and sphingolipid. It is formulated into an oral dosage form and the astaxanthin is 0.1 to 15 percent by weight of the at least one phospholipid, glycolipid, and sphingolipid.

Abstract: A dietary supplement composition and associated method of use has the composition formulated in a therapeutic amount to treat and alleviate symptoms of joint pain in a person having joint pain. The composition includes astaxanthin and microbial fermented, low molecular weight hyaluronic acid or sodium hyaluronate (hyaluronan). The composition also includes at least one of a phospholipid, glycolipid, and sphingolipid. It is formulated into an oral dosage form and the astaxanthin is 0.1 to 15 percent by weight of the at least one phospholipid, glycolipid, and sphingolipid.

Abstract: A method of treating photo-induced ocular fatigue and associated reduction in speed of ocular focus in humans includes administering a therapeutic amount of a dietary supplement composition comprising a carrier admixed with carotenoids, which may include 0.5 to 8.0 mg of astaxanthin, 2.0 to 15 mg of lutein and 0.2 to 12.0 mg of zeaxanthin. The composition is formulated into an oral dosage form as a single dosage capsule.

Abstract: Technology for auditing monitors is provided. In one example, a method may include identifying a virtualized computing system to be audited. The method may further include identifying existing monitors on the virtualized computing system for monitoring the virtualized computing system and collecting metrics. The existing monitors may be compared against defined monitors specified in a data store for the virtualized computing system to identify missing monitors absent from the virtualized computing system. The virtualized computing system having the missing monitors may be flagged.

Abstract: A dietary supplement composition is formulated in a therapeutic amount to treat and alleviate symptoms of joint pain. The composition includes pro-inflammatory low molecular weight microbial fermented sodium hyaluronate fragments having a molecular weight of 0.5 to 300 kilodaltons (kDa) and astaxanthin in an oral dosage form. The astaxanthin may be derived from a natural or synthetic ester or synthetic diol. The composition may include a mixture of cartilage and salt and boron.

Abstract: A dietary supplement includes comprising a therapeutic amount of astaxanthin derived from a synthetic or natural ester or diol, and at least one of a phospholipid, glycolipid, and sphingolipid, and formulated into an oral dosage form, wherein the astaxanthin is 0.1 to 15 percent by weight of the at least one phospholipid, glycolipid, and sphingolipid. The composition includes 0.5 to 12 mg of astaxanthin and may be used to treat low density lipoprotein (LDL) oxidation in humans and other diseases, disorders and impairments.

Abstract: A composition of matter comprises a shelf stable, partially defatted supercritical CO2 fluid solvent extracted whole grain flour derived from a cracked biomass of perilla frutescens, the flour comprising minerals and 2 to 8 percent of native seed oil, 35 to 45 percent protein, and 35 to 45 percent fiber.

Abstract: A dietary supplement includes comprising a therapeutic amount of astaxanthin derived from a synthetic or natural ester or diol, and at least one of a phospholipid, glycolipid, and sphingolipid, and formulated into an oral dosage form, wherein the astaxanthin is 0.1 to 15 percent by weight of the at least one phospholipid, glycolipid, and sphingolipid. The composition includes 0.5 to 12 mg of astaxanthin and may be used to treat low density lipoprotein (LDL) oxidation in humans and other diseases, disorders and impairments.

Abstract: A dietary supplement composition is formulated in a therapeutic amount to treat and alleviate symptoms of hot flashes in a female subject, such as experiencing symptoms of perimenopause. The composition includes a phytoestrogen and lycopene in an oral dosage form. The phytoestrogen may include a plant lignan including at least one of Matairesinol, 7-hydroxymatairesinol, Secoisolariciresinol, Lariciresinol and Pinoresinol. The lycopene may include a lycopene complex having at least one of phytoene, phytofluene, beta-carotene, tocopherols and phytosterols.

Abstract: A dietary supplement composition is formulated in a therapeutic amount to treat and alleviate symptoms of joint pain. The composition includes pro-inflammatory low molecular weight microbial fermented sodium hyaluronate fragments and glucosamine in an oral dosage form.

Abstract: In accordance with a non-limiting example, an algae based oil is used in place of a krill oil to treat low density lipoprotein (LDL) oxidation in humans by administering a therapeutic amount of a dietary supplement composition comprising an algae based oil comprising glycolipids and phospholipids and Eicosapentaenoic (EPA) fatty acids in combination with astaxanthin derived from Haematococcus pluvialis (Hp) in an oral dosage form, wherein the astaxanthin derived from Haematococcus pluvialis (Hp) is 0.1 to 4.0 percent by weight of the algae based oil.

Abstract: A dietary supplement composition is formulated in a therapeutic amount to treat and alleviate symptoms of joint pain. The composition includes pro-inflammatory low molecular weight microbial fermented sodium hyaluronate fragments and glucosamine in an oral dosage form.

Abstract: A dietary supplement composition is formulated in a therapeutic amount to treat and alleviate symptoms of hot flashes in a female subject, such as experiencing symptoms of perimenopause. The composition includes a phytoestrogen and lycopene in an oral dosage form. The phytoestrogen may include a plant lignan including at least one of Matairesinol, 7-hydroxymatairesinol, Secoisolariciresinol, Lariciresinol and Pinoresinol. The lycopene may include a lycopene complex having at least one of phytoene, phytofluene, beta-carotene, tocopherols and phytosterols.

Abstract: A dietary supplement composition is formulated in a therapeutically effective amount to treat the eye of an individual. The composition includes a perilla seed oil extract, astaxanthin, and at least one carotenoid selected from the group consisting of lutein, trans-zeaxanthin and meso-zeaxanthin.

Abstract: Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA either alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.

Abstract: Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA either alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.

Abstract: Technology for message grouping is provided. In one example, a method may include identifying message addresses to group together. Messages from the message addresses may be modified to include a common sender group attribute according to a defined address grouping rule. The messages exchanged with the message senders may be arranged as a grouped conversation using the common sender group attribute.